Panoptes Pharma   Report issue

For profit Phase 2
Founded: Vienna Austria (2013)
Status: Acquired by Eyegate Pharmaceuticals, Inc. (2020)

Organization Overview

First Clinical Trial
2017
NCT03634475
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Panoptes Pharma | Panoptes Pharma GmbH

Active Ingredients

Drugs in Phase 2 Trials (1)

pp-001 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Keratoconjunctivitis (Phase 1)

Uveitis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1